08/05/2022 | Press release | Distributed by Public on 08/05/2022 12:11
Brussels (Belgium), 5 August 2022 - 20:05 (CEST) - Regulated information
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 3 August 2022.
FMR LLC., notified that, following a disposal of UCB shares with voting rights by its affiliates, the shareholding in UCB SA/NV of a controlled entity decreased and crossed downwards the 3% threshold, on 1 August 2022.
On 1 August 2022, FMR LLC. (taking into account the holding of its affiliates) owned 7 509 016 UCB shares with voting rights, representing 3.86% of the total number of shares issued by the company (194 505 658), versus 4.99 % (9 698 901 UCB shares) in the previous notification dated 24 May 2022.
2. Content of the notification
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.
For further information, contact UCB:
Investor Relation
Antje Witte
T +32 2 559 94 14
[email protected]
Corporate Communications
Laurent Schots
T+32 2 559 92 64
[email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news